NMTCNMTCHealthcare · Medical Devices

NMTC Stock Forecast: NeuroOne Medical Technologies Corp. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.65
−3.39% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 36 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$6.1M
Ticker Nerd rank
36/ 100
Median analyst target
$8.00
Analysts covering
—
Revenue$2.0M+16.3% y/y
Operating income−$2.4M
Net income−$2.0M
Free cash flow−$1.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.5%
1M
−33.7%
YTD
−85.7%
1Y
−81.9%
From 52W high
−88.9%
From 52W low
0.0%
$0.65
$5.89
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores NeuroOne Medical Technologies Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
36/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
58
Revisions
56
Issuance
53
Accruals
47
Volatility
47
Value
28
Growth
22
Momentum
4

Quality (58): The business earns solid, repeatable profits on what it owns.

Momentum (4): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NMTC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NMTC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26NMTCHigh $8.80Median $8.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026Maxim GroupMaintainsBuy$13 → $5.00
13 May 2026Ladenburg ThalmannMaintainsBuy$1.60 → $8.00
2 Mar 2026Jones TradingInitiatesBuy—
9 Sept 2025Maxim GroupInitiatesBuy—
5 May 2025Ladenburg ThalmannInitiatesBuy—
15 Aug 2023Alliance Global PartnersMaintainsBuy—
28 Mar 2022Craig-HallumDowngradeHold—
3 Dec 2021Alliance Global PartnersInitiatesBuy—
15 Nov 2021Craig-HallumInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

NMTC appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

NMTC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, NeuroOne Medical Technologies Corp. returned −81.9% against +6.9% for the S&P 500, dividends included.

NMTC vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Jan 26Apr 26Jul 26Oct 26NMTCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NMTC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.5×

Cheaper than 79% of US stocks

Price / book
1.6×

Cheaper than 51% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
16.3%

Higher than 65% of US stocks

Earnings growth (YoY)
—
Gross margin
59.9%

Higher than 73% of US stocks

Operating margin
−63.4%

Higher than 17% of US stocks

Net margin
—
Returns & dividend
Return on equity
−124.7%

Higher than 11% of US stocks

Return on assets
−58.1%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • NeuroOne Medical Technologies Corp. has a market value of $6.1M and an enterprise value of $4.3M.

  • Revenue in the twelve months to 30 June 2026: $9.5M. The latest quarter grew 16.3% year on year.

  • Net income over the same four quarters: −$7.4M, a −78.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$7.2M.

  • NeuroOne Medical Technologies Corp. spent $70K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 8.7M.

  • NeuroOne Medical Technologies Corp. employs 18 people — $526K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

NMTC and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
NMTCNeuroOne Medical Technologies Corp.$6.1M36
VNRXVolitionRX Ltd.$5.8M53
ARAYAccuray, Inc.$6.2M46
POASPhaos Technology Holdings (Cayman) Ltd.$5.1M2
BDMDBaird Medical Investment Holdings Ltd.$5.1M59
BMRABiomerica, Inc.$5.0M11
WOKWORK Medical Technology Group Ltd.$4.9M16

Take a look at NMTC’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own NeuroOne Medical Technologies Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about NMTC

How does Ticker Nerd's model rank NMTC?

As at 21 Nov 2026, NeuroOne Medical Technologies Corp. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (58 of 100).

What is the NMTC stock forecast for 2030?

No analyst covering NeuroOne Medical Technologies Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NMTC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $8.8 over the next 12 months.

How has NMTC stock performed over the past year?

NeuroOne Medical Technologies Corp. returned -81.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NeuroOne Medical Technologies Corp. do?

NeuroOne Medical Technologies Corporation is a medical technology company focused on diagnostic and therapeutic solutions for neurological disorders. The company develops and commercializes thin-film electrode technology for continuous electroencephalogram and stereoelectroencephalography recording, along with minimally invasive systems for brain ablation, stimulation, and drug delivery.

Company

About NeuroOne Medical Technologies Corp.

NeuroOne Medical Technologies Corporation is a medical technology company focused on diagnostic and therapeutic solutions for neurological disorders. The company develops and commercializes thin-film electrode technology for continuous electroencephalogram and stereoelectroencephalography recording, along with minimally invasive systems for brain ablation, stimulation, and drug delivery. Its product portfolio includes Evo cortical electrodes, Evo sEEG electrodes, and OneRF ablation systems designed for neurosurgery, neurology, and pain management applications. NeuroOne Medical Technologies Corporation serves clinical settings that treat conditions such as epilepsy, trigeminal neuralgia, Parkinson’s disease, dystonia, essential tremor, and chronic pain. Based in Eden Prairie, Minnesota, the company plays a specialized role in the neurotechnology market by supporting more precise monitoring and treatment options for patients with complex brain and nerve-related disorders.

CEO Mr. David A. Rosa M.D. · 18 employees · United States · https://nmtc1.com